Cargando…
The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
The discovery of the hepatitis C virus (HCV) NS5A replication inhibitor daclatasvir (1) had its origins in a phenotypic screening lead. However, during the optimization campaign, it was observed that some members of the chemotype underwent a radical dimerization under the assay conditions. This redi...
Autores principales: | Meanwell, Nicholas A., Belema, Makonen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122418/ http://dx.doi.org/10.1007/7355_2018_47 |
Ejemplares similares
-
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
por: Zhou, Nannan, et al.
Publicado: (2016) -
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2020) -
Corrigendum: A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2021) -
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
por: Gao, Min, et al.
Publicado: (2010) -
HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice
por: Lee, Seung-Hoon, et al.
Publicado: (2018)